Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.

ABSTRACT:

Objective

To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes.

Research design and methods

Sixteen subjects with type 2 diabetes (age 59.8 ± 6.8 years, BMI 29.1 ± 4.8 kg/m(2), HbA(1c) 6.97 ± 0.61) on oral blood glucose-lowering treatment were included. Participants received vildagliptin 50 mg b.i.d. or acarbose 100 mg t.i.d. for four consecutive weeks in a randomized, double-blind, cross-over design. At the end of each treatment period, we measured forearm vasodilator responses to intra-arterially administered acetylcholine (endothelium-dependent vasodilator) and sodium nitroprusside (endothelium-independent vasodilator).

Results

Infusion of acetylcholine induced a dose

SUBMITTER: van Poppel PC 

PROVIDER: S-EPMC3161271 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature